Business Wire

CONVERT-GROUP

Share
Convert Group Study: COVID-19 Drew More Than 2.7 Billion Visits to Global ePharmacies in 96 Countries in Q1'21

Consumers and patients globally have turned to digital platforms to purchase their prescription (Rx), non-prescription (OTC) medication and parapharmacy products with more than 2.7 billion online visits to leading ePharmacies across 96 countries in Q1’21. This represents an astonishing 43% growth rate compared to Q1’20. The details of this global research have been published online at epharmacydata.com .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005087/en/

The study highlights the unique opportunity for Consumer Healthcare Retailers and Manufacturers to address the new habits of consumers and patients purchasing their prescription (Rx) and non-prescription (OTC) medicine and parapharmacy products online. Out of the 96 countries having at least 1 online pharmacy, consumers can order their prescription drugs online in 47 countries. The COVID-19 pandemic, wide adoption of electronic prescription , and the modernisation of last mile logistics have worked wonders towards allowing the sale of prescription drugs through eCommerce in the last year, something that was unimaginable 5 years ago in most of the 47 countries. For example, in April 2020 the State Duma of the Russian Federation legalized within days, after years of deliberation, the online sales of prescription and over-the-counter drugs, with the exception of narcotic and psychotropic drugs.

Online Pharmacies are one of the fastest rising eCommerce sectors in the world:

Amazon invested heavily in the industry with the acquisition of PillPack in 2020.

JD Health , a unit of JD.com Inc ., increased its revenue, jumping to a +76% year-over-year growth to $1.34 billion, in the first six months of 2020.

Alibaba -backed Alibaba Health posted a +74% revenue increase over the March to September 2020 period.

● While brick and mortar pharmacy chains such as CVS & Walgreens in the USA surpass 100 million online visits and Boots averages 20 million online visits , pure ecommerce players such as 1mg in India, Consultaremedios in Brazil and Apteka in Russia have been growing extremely fast, with more than 20 million visits per month on average for the last 6 months, disrupting global markets with services such as doctors appointments booking, marketplace capabilities and online consultations.

The research was performed by Convert Group , the leading global ePharmacy Data firm that Consumer Healthcare & FMCG Manufacturers such as Bayer, GSK, J&J, L'Oréal, Nestlé, P&G, Perrigo, Pierre Fabre, Reckitt Benckiser, Roche, Unilever, and others trust for their data-driven strategy and sell-out insights on the eCommerce channel. Traffic data was drawn with permission from Similarweb , the global leading provider of digital market intelligence, for 3.478 Online Pharmacies in 96 Countries across all continents.

Key findings include:

47 in 96 countries allow the online ordering of prescription medicine (Rx)

88 in 96 countries allow the online ordering of non-prescription medicine (OTC). The only countries prohibiting it are Algeria, Cyprus, Greece, Morocco and Turkey.

North America was the region with the highest growth, with online visits increasing by +114%. Online visits increased by +80% in South America and +78% in Northern Africa .

Sweden was the leading country with 18,001 visits to online pharmacies per 1,000 residents , followed by 13,208 visits per 1,000 residents in Bulgaria, 10,418 visits per 1,000 residents in Lithuania, and x 9,739 visits per 1,000 residents in the UK.

Brazil has the most tier1 online pharmacies (pharmacies with more than 5M visits per average month in Q1’21) with 6 total, followed by Russia with 4, and the U.S. , UK and India with 3 each.

Panayotis Gezerlis , CEO of Convert Group, commented: "During the first lockdown we saw the majority of patients & consumers across countries adopting online purchase habits from ePharmacies with tremendous speed. Many of the newcomers were also supported by ePrescription legislation being adopted across a number of countries, beside the current global eCommerce hype. In some countries more than 20% of Consumer Healthcare revenues are now originating online. We feel that, with the current growth trends, it is likely that by 2035 more than half of the total sales of Rx, OTC and parapharmacy products will be happening online, in the majority of global markets."

The results of the study are now published on the newly-launched epharmacydata.com and will be distributed at the 2021 Global ePharmacy Summit on September 22 - 24, 2021, hosted by Convert Group. epharmacydata.com will be updated monthly to offer the global Consumer Healthcare community insights and data on one of the fastest rising sectors of global eCommerce.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release

New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release

Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release

First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye